JP2014527529A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527529A5
JP2014527529A5 JP2014526090A JP2014526090A JP2014527529A5 JP 2014527529 A5 JP2014527529 A5 JP 2014527529A5 JP 2014526090 A JP2014526090 A JP 2014526090A JP 2014526090 A JP2014526090 A JP 2014526090A JP 2014527529 A5 JP2014527529 A5 JP 2014527529A5
Authority
JP
Japan
Prior art keywords
hydroxy
alkyl
methylsulfonamido
cyclopropyl
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014526090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527529A (ja
JP6367712B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/050268 external-priority patent/WO2013028371A1/en
Publication of JP2014527529A publication Critical patent/JP2014527529A/ja
Publication of JP2014527529A5 publication Critical patent/JP2014527529A5/ja
Application granted granted Critical
Publication of JP6367712B2 publication Critical patent/JP6367712B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014526090A 2011-08-19 2012-08-10 C型肝炎ウイルス感染の治療のためのベンゾフラン化合物 Expired - Fee Related JP6367712B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US61/525,440 2011-08-19
US201261650681P 2012-05-23 2012-05-23
US61/650,681 2012-05-23
PCT/US2012/050268 WO2013028371A1 (en) 2011-08-19 2012-08-10 Benzofuran compounds for the treatment of hepatitis c virus infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016249387A Division JP2017125010A (ja) 2011-08-19 2016-12-22 C型肝炎ウイルス感染の治療のためのベンゾフラン化合物

Publications (3)

Publication Number Publication Date
JP2014527529A JP2014527529A (ja) 2014-10-16
JP2014527529A5 true JP2014527529A5 (https=) 2015-09-17
JP6367712B2 JP6367712B2 (ja) 2018-08-01

Family

ID=47746761

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014526090A Expired - Fee Related JP6367712B2 (ja) 2011-08-19 2012-08-10 C型肝炎ウイルス感染の治療のためのベンゾフラン化合物
JP2016249387A Pending JP2017125010A (ja) 2011-08-19 2016-12-22 C型肝炎ウイルス感染の治療のためのベンゾフラン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016249387A Pending JP2017125010A (ja) 2011-08-19 2016-12-22 C型肝炎ウイルス感染の治療のためのベンゾフラン化合物

Country Status (38)

Country Link
US (2) US8927593B2 (https=)
EP (2) EP3199531A1 (https=)
JP (2) JP6367712B2 (https=)
KR (1) KR101913800B1 (https=)
CN (1) CN103732065B (https=)
AR (1) AR087563A1 (https=)
AU (1) AU2012299295B2 (https=)
BR (1) BR112014002845A2 (https=)
CA (1) CA2844086A1 (https=)
CL (2) CL2014000393A1 (https=)
CO (1) CO6862153A2 (https=)
CR (1) CR20140078A (https=)
CY (1) CY1118399T1 (https=)
DK (1) DK2744332T3 (https=)
DO (1) DOP2014000034A (https=)
EA (1) EA032841B1 (https=)
ES (1) ES2611731T3 (https=)
HR (1) HRP20161743T1 (https=)
HU (1) HUE030300T2 (https=)
IL (1) IL230487B (https=)
IN (1) IN2014CN00572A (https=)
JO (1) JO3281B1 (https=)
LT (1) LT2744332T (https=)
MA (1) MA35443B1 (https=)
ME (1) ME02588B (https=)
MX (1) MX354676B (https=)
PE (1) PE20141201A1 (https=)
PH (1) PH12014500385A1 (https=)
PL (1) PL2744332T3 (https=)
PT (1) PT2744332T (https=)
RS (1) RS55462B1 (https=)
SG (1) SG10201606883QA (https=)
SI (1) SI2744332T1 (https=)
SM (2) SMT201700028T1 (https=)
TW (1) TWI538915B (https=)
UY (1) UY34274A (https=)
WO (1) WO2013028371A1 (https=)
ZA (1) ZA201401020B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014001833A (es) * 2011-08-17 2014-02-27 Glaxosmithkline Llc Metodos terapeuticos.
PH12014500385A1 (en) 2011-08-19 2020-06-22 Glaxo Group Ltd Benzofuran compounds for the treatment of hepatitis c virus infections
SG11201703645XA (en) * 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Long acting pharmaceutical compositions for hepatitis c
KR20170081257A (ko) * 2014-11-10 2017-07-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 C형 간염에 대한 조합 장기 작용 조성물 및 방법
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
US11738088B2 (en) 2016-08-01 2023-08-29 University of Pittsburgh—of the Commonwealth System of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
CA3055194A1 (en) * 2017-03-02 2018-09-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
CA3088347A1 (en) * 2018-01-17 2019-07-25 Glaxosmithkline Intellectual Property Development Limited Pi4kiii.beta. inhibitors
EP4049680A4 (en) * 2019-10-25 2024-01-10 Sumitomo Pharma Co., Ltd. NEW SUBSTITUTED CONDENSED RING CONNECTION
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统
MX2023007150A (es) * 2020-12-18 2023-09-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
AU5920400A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
ES2571219T3 (es) 2001-01-25 2024-09-23 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulación de compuestos de ácido borónico
EA009943B1 (ru) * 2002-11-01 2008-04-28 Вирофарма Инкорпорейтед Соединения бензофурана, композиции и способы лечения и профилактики инфекций, вызванных вирусом гепатита с, и связанных с ним заболеваний
AU2006349612A1 (en) 2005-12-01 2008-05-02 Wyeth Anthranilic acid derivatives useful in treating infection with Hepatitis C virus
PT1988779E (pt) 2006-02-16 2015-09-04 Anacor Pharmaceuticals Inc Moléculas pequenas contendo boro como agentes antiinflamatórios
EP2015757A4 (en) * 2006-05-02 2011-01-26 Anacor Pharmaceuticals Inc HYDROLYSERESISTENT, BOROYED THERAPEUTIC USES
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
MX2009013332A (es) 2007-06-08 2010-01-25 Mannkind Corp Inhibidores de ire-1 alfa.
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
ATE539070T1 (de) * 2008-02-14 2012-01-15 Hoffmann La Roche Heterozyklische antivirale verbindungen
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
US7737157B2 (en) 2008-08-29 2010-06-15 Hutchison Medipharma Enterprises Limited Pyrimidine compounds
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
WO2011103063A1 (en) * 2010-02-19 2011-08-25 Glaxo Group Limited Therapeutic compounds
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
WO2012067664A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
AU2011329485A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
MX2014001833A (es) * 2011-08-17 2014-02-27 Glaxosmithkline Llc Metodos terapeuticos.
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
PH12014500385A1 (en) 2011-08-19 2020-06-22 Glaxo Group Ltd Benzofuran compounds for the treatment of hepatitis c virus infections

Similar Documents

Publication Publication Date Title
JP2014527529A5 (https=)
JP2016538313A5 (https=)
JP2014530900A5 (https=)
RU2485131C2 (ru) Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой и содержащие их противогрибковые средства
JP2017537949A5 (https=)
JP2013535487A5 (https=)
RU2015151502A (ru) Химические соединения
JP2012505836A5 (https=)
JP2016525102A5 (https=)
JP2011502958A5 (https=)
RU2011144763A (ru) 6-(3-азабицикло[3.1.0]гекс-3-ил)-2-фенилпиримидины
RU2011108026A (ru) Комбинированная терапия туберкулеза
RU2015120216A (ru) Ингибиторы тирозинкиназы брутона
JP2014523851A5 (https=)
JP2015509103A (ja) イミダゾピロリジノン化合物
HRP20171028T1 (hr) Indolski i indazolski spojevi koji aktiviraju ampk
RU2014115290A (ru) Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов
RU2009125019A (ru) Производные карбоновой кислоты
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
RU2018114077A (ru) Биарильное производное и содержащее его лекарственное средство
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2014505107A5 (https=)
BR112014011981A2 (pt) formulações farmacêuticas
JP2019501879A5 (https=)
JP2016540045A5 (https=)